Cellectar Biosciences, Inc. (CLRB)
| Market Cap | 21.02M +187.9% |
| Revenue (ttm) | n/a |
| Net Income | -20.84M |
| EPS | -6.35 |
| Shares Out | 7.99M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 17,543 |
| Open | 2.570 |
| Previous Close | 2.600 |
| Day's Range | 2.552 - 2.620 |
| 52-Week Range | 2.200 - 6.520 |
| Beta | 0.55 |
| Analysts | Strong Buy |
| Price Target | 11.50 (+337.26%) |
| Earnings Date | Aug 13, 2026 |
About CLRB
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The company’s lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom’s macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin’s lymphoma cohort; Phase 1 cli... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for CLRB stock is "Strong Buy." The 12-month stock price target is $11.5, which is an increase of 337.26% from the latest price.
News
Cellectar Biosciences to Report Second Quarter Financial Results and Host a Conference Call on Thursday, August 13, 2026
FLORHAM PARK, N.J., July 30, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for ...
Cellectar Biosciences publishes iopofosine I 131 dose-escalation study results
Cellectar Biosciences (CLRB) announced the publication of results from a Phase 1 dose-escalation study evaluating iopofosine I 131 in combination with low-dose dexamethasone in 31 patients with heavil...
Cellectar Biosciences Announces Publication of Phase 1 Study of Iopofosine I 131 in Peer-Reviewed Journal Cancers
Demonstrated Favorable Safety Profile and Preliminary Clinical Activity in Relapsed/Refractory Multiple Myeloma
Cellectar Biosciences initiated with a Buy at Brookline
Brookline initiated coverage of Cellectar Biosciences (CLRB) with a Buy rating and $15 price target
Cellectar Biosciences to Highlight Compelling New Efficacy Data from Phase 2b CLOVER WaM Study of Iopofosine I 131 in r/r Waldenström Macroglobulinemia at the American Society of Clinical Oncology Annual Meeting
Approximately 80% Major Response Rate and Duration of Response Exceeding 16 Months in Subset Analysis of Patients Treated with Iopofosine I 131 Immediately Post-BTKi Therapy
Cellectar Biosciences Slides: Corporate presentation
Cellectar Biosciences has posted slides in relation to its latest quarterly earnings report, which was published on June 1, 2026.
Cellectar Biosciences Registration statement: Registration filing
Cellectar Biosciences filed a registration statement on May 29, 2026, providing details about a securities offering with the SEC.
Cellectar Biosciences Proxy statement: Proxy filing
Cellectar Biosciences filed a proxy statement on May 28, 2026, providing details for shareholder voting and corporate governance matters.
Cellectar Biosciences Proxy statement: Proxy filing
Cellectar Biosciences filed a proxy statement on May 28, 2026, providing details for shareholder voting and corporate governance matters.
Cellectar Biosciences files to sell 51.21M shares of common stock for holders
17:08 EDT Cellectar Biosciences (CLRB) files to sell 51.21M shares of common stock for holders
Cellectar Biosciences Registration statement: Registration filing
Cellectar Biosciences filed a registration statement on May 19, 2026, providing details about a securities offering with the SEC.
Cellectar Biosciences Proxy statement: Proxy filing
Cellectar Biosciences filed a proxy statement on May 18, 2026, providing details for shareholder voting and corporate governance matters.
Cellectar Biosciences assumed with a Buy at Ladenburg
Ladenburg assumed coverage of Cellectar Biosciences (CLRB) with a Buy rating and $10 price target
Cellectar Biosciences Earnings Call Transcript: Q1 2026
Positive 12-month iopofosine data in WM and a $140M financing mark a pivotal quarter, enabling phase III trial initiation and potential accelerated FDA approval. CLR 125 advances in TNBC, with strong financial runway into 2027.
Cellectar Biosciences Quarterly report: Q1 2026
Cellectar Biosciences has published its Q1 2026 quarterly earnings report on May 14, 2026.
Cellectar Biosciences Earnings release: Q1 2026
Cellectar Biosciences released its Q1 2026 earnings on May 14, 2026, summarizing the period's financial results.
Cellectar Biosciences reports Q1 EPS ($1.33), consensus ($1.88)
“The first part of 2026 was a pivotal period for Cellectar as we executed across our pipeline and capital strategies to position the company for value creation,” said James Caruso,…
Cellectar Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates
Announced Positive 12-month Follow-on Data for Iopofosine I 131 in relapsed/refractory Waldenström Macroglobulinemia (r/r WM)
Cellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Thursday, May 14, 2026
FLORHAM PARK, N.J., May 11, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for t...
Cellectar Biosciences price target lowered to $11 from $14 at Roth Capital
Roth Capital analyst Jonathan Aschoff lowered the firm’s price target on Cellectar Biosciences (CLRB) to $11 from $14 and keeps a Buy rating on the shares. Cellectar Biosciences reported positive…
Cellectar Biosciences reports CLOVER WaM trial achieves primary endpoint
Cellectar Biosciences (CLRB) announced updated and mature 12-month follow-up data from its Phase 2b CLOVER WaM clinical trial evaluating iopofosine I 131 in patients with relapsed or refractory Walden...
Cellectar Biosciences Reports Positive 12-Month Follow-Up Data from Phase 2b CLOVER WaM Study Demonstrating Durable Responses and Efficacy of Iopofosine I 131 in r/r Waldenström Macroglobulinemia
83.6% ORR and 61.8% MRR achieved in heavily pretreated population with median duration of response of 17.8 months FDA-requested dataset with ≥12-month follow-up on all patients strengthens regulatory ...
Cellectar Biosciences Announces Oversubscribed Financing Up to $140 Million
Oversubscribed Financing Led by Nantahala Capital with Participation from Balyasny Asset Management, Caligan Partners, Janus Henderson Investors, SilverArc Capital Management, Stonepine Capital Manage...
Cellectar Biosciences enrolls first patient in CLR 121125 trial
Cellectar Biosciences (CLRB) announced that the first patient has been enrolled in the Phase 1b trial of CLR 121125 for the potential treatment of triple negative breast cancer. Published first…
Cellectar Enrolls First Patient in CLR 125 Auger-Emitting Radioconjugate Phase 1b Clinical Trial Targeting Refractory Triple Negative Breast Cancer (TNBC)
Study will evaluate tumor-specific uptake, safety, tolerability, and preliminary efficacy signals of CLR 125 in refractory TNBC, to determine recommended Phase 2 dose Study will evaluate tumor-specifi...